The aim is to reduce laboratory burden in low-resource settings while enabling timely clinical interventions that improve ...

NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...

The iRR6 model refines risk stratification for intermediate-1 myelofibrosis patients, incorporating ruxolitinib dosing, spleen reduction, and transfusion needs. Validation in an external cohort ...

Investigators designed and externally validated a prostate cancer death prediction model for risk stratification of men at the point of PSA screening.

The new MMAI risk grouping system can potentially reduce overtreatment and undertreatment of localized prostate cancer. Deep learning multimodal artificial intelligence (MMAI) models outperformed ...

The multi-modal approach leverages additional information from the patient's tumor sample, using Natera's AI models trained on long-term molecular and clinical outcomes from Natera's proprietary ...

Model was developed from the prostate cancer screening group of the PLCO and validated externally in a VA population ...

Prostate cancer (PCa) represents a highly heterogeneous disease that requires tools to assess oncologic risk and guide patient management and treatment planning. Current models are based on various ...

An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, ...